An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone who has been taking tirzepatide (a prescription drug for weight loss and diabetes) wrote that after adding KPV — a different peptide product — they felt their appetite suppression from tirzepatide weaken. They stopped the KPV and kept another peptide called GLOW, and said their appetite suppression returned. That’s the report: an individual's observation, not a controlled study. KPV is a short peptide that you’ll mostly see sold online as a research or skincare product. It’s different from the diabetes/weight-loss drugs like tirzepatide or semaglutide. These diabetes drugs are designed to act on the brain and gut to reduce hunger and slow stomach emptying. KPV doesn’t have the same established role; there’s very little clinical data about what it does when people take it alongside prescription medicines. The “research” in this case is a single person’s experience — an anecdote. That means one person noticed their tirzepatide seemed less effective at suppressing appetite while they were also taking KPV, and the feeling reversed when they stopped KPV. Anecdotes can be useful for raising questions, but they don’t prove cause and effect. We don’t know details like doses, timing, other health factors, or whether something else (stress, sleep, food, a supply issue with tirzepatide) could explain the change. Why this might matter: many people using tirzepatide or similar drugs are very attuned to changes in appetite and weight. If a commonly available peptide like KPV did interfere with the effects of prescription weight-loss drugs, that would be important for safety and effectiveness. People combining over-the-counter peptides with prescription medications should be cautious because interactions are possible and not well-studied. Important caveats: this is not evidence that KPV disrupts tirzepatide. It’s a single report. KPV products sold online often lack regulatory oversight, consistent dosing, or safety testing. Mixing unregulated peptides with prescription drugs carries unknown risks. If someone thinks a product is changing how their medication works, they should stop the unregulated product and talk with their prescribing clinician before making changes. Also, side effects from tirzepatide can fluctuate on their own, and supply or injection technique issues can mimic reduced effect. Bottom line: an individual noticed appetite returned while taking KPV with tirzepatide, but that’s only an anecdote — it raises a question worth discussing with a healthcare provider, not proof that KPV blocks tirzepatide.
Source: r/Peptides